Description
Beyond Spring develops innovative immuno-oncological cancer treatments through a robust system of in-house development and collaboration with the University of Washington on drug discovery using the ubiquitination platform. The company's main asset, plinabulin, is undergoing two phase 3 global clinical trials as a direct anti-cancer agent in the treatment of non-small cell lung cancer (NSCLC) and prevention of chemotherapy-induced neutropenia (CIN).
BeyondSpring has an experienced management team with years of experience in bringing medicines to the global market.
Story
Since 2010, Beyond Spring's mission has been to develop transformative cancer treatments that will improve clinical outcomes for patients with high unmet needs.